In soft tissue sarcoma, pazopanib improves PFS without affecting HRQoL
the ONA take:
Pazopanib improved progression-free survival but did not impact health-related quality of life in patients with soft tissue sarcoma who experienced disease progression during or after prior chemotherapy, according to a new study published in the journal Cancer.
The global, double-blind, phase III PALETTE trial found that pazopanib 800 mg as second-line or later treatment improved median progression-free survival by 3 months compared with placebo in patients with advanced soft tissue sarcoma. Researchers also found that the most common adverse events associated with pazopanib treatment were diarrhea, fatigue, hypertension, nausea, and weight loss.
Researchers also conducted an exploratory analysis to evaluate the impact of pazopanib treatment on health-related quality of life. Patients were assessed using the 30-item core EORTC Quality-of-Life Questionnaire at baseline and at 4, 8, and 12 weeks of treatment.
Results showed that there was no statistically significant different in global health status between pazopanib and placebo; however, those receiving pazopanib reported significantly worse scores for diarrhea, fatigue, loss of appetite, and nausea/vomiting than those who received placebo. Researchers found that health-related quality of life score tended to decrease over time in both treatment groups.
Pazopanib (Votrient) was initially approved by the U.S. Food and Drug Administration in 2009 for the treatment of patients with advanced renal cell carcinoma.
Pazopanib improved PFS but did not impact HRQoL in patients with soft tissue sarcoma who experienced disease progression during or after prior chemo.
- Novel Colonoscopy Prep Is Poised to Improve Screening Rates for Colon Cancer
- PPIs Negatively Impact Outcomes of Patients Treated With Capecitabine
- How Physical Changes From Breast Cancer Affect Self-Image: Considerations for Clinicians
- Panobinostat Modestly Improves OS in Relapsed Multiple Myeloma
- Short-Term Intervention May Have Long-term Diet Effect in Hispanic Breast Cancer Survivors
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- Pseudohyperkalemia: False Potassium Levels Occur in a Patient With Lymphoma
- Atezolizumab Granted FDA Approval for Specific Cases of NSCLC
- Low-Dose Sublingual Fentanyl Safe, Effective in Patients Receiving Lower Opioid Doses
- High U.S. Economic Burden for Vaccine-Preventable Diseases
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|